1276121-44-8

Basic information

• Product Name: [2-(benzyloxycarbonyl-methyl-amino)-ethyl]-dicarbamic acid tert-butyl ester
• Synonyms: [2-(benzyloxycarbonyl-methyl-amino)-ethyl]-dicarbamic acid tert-butyl ester
• CAS NO: 1276121-44-8
• Molecular Weight: 408.495
• Mol File: 1276121-44-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: [2-(benzyloxycarbonyl-methyl-amino)-ethyl]-dicarbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(benzyloxycarbonyl-methyl-amino)-ethyl]-dicarbamic acid tert-butyl ester(1276121-44-8)
• EPA Substance Registry System: [2-(benzyloxycarbonyl-methyl-amino)-ethyl]-dicarbamic acid tert-butyl ester(1276121-44-8)

Safety Data

• Hazardous Substances Data: 1276121-44-8(Hazardous Substances Data)

Upstream product

• 1221593-52-7 methyl-[2-(2,2,2-trifluoro-acetylamino)-ethyl]carbamic acid benzyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 19023-94-0 (2-aminoethyl)-methylcarbamic acid,benzyl ester 

Downstream Products

• 105983-83-3 tert-butyl 2-tert-butyloxycarbonylaminoethyl(methyl)carbamate 

Relevant articles and documents

An enzyme and its optional [...] modified ketone and inhibitor composition comprising (by machine translation)

PROBLEM TO BE SOLVED: ketone-containing acrylic misuse, abuse or overload is prevented for a new takable amt. provitamin drag pain. SOLUTION: a compound represented by the following formula is represented, in which the drag oxystyrene provitamin hydrocodone ketone-containing acrylic. Pre-selected drug profile is modified and the ketone and schisandrin [...] holding hung contg. compsn. method for administration to a patient. Selected drawing: no (by machine translation)

Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug

The embodiments provide Compound KC-7, N-1-[(S)-2-(oxycodone-6-enol-carbonyl-methyl-amino)-2-carbonyl-sarcosine-ethyl amine]-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-7, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.